Cost-utility and budget impact analysis of tocilizumab for the treatment of refractory systemic juvenile idiopathic arthritis in Thailand.

ABSTRACT:

Objectives

This study aimed to analyse the cost-utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand.

Design

Economic evaluation using a decision-analytical model.

Setting

Thailand.

Participants

Patients with refractory sJIA who were ≥2 years old.

Methods

The use of tocilizumab as an add-on therapy to standard treatment was compared with standard treatment alone. A simulated health state transition model was used to estimate the lifetime costs and health outcomes from a societal perspective. Direct medical costs were collected from tertiary hospital databases while direct non-medical costs were derived from interviews. Health-related quality of lif

SUBMITTER: Kittiratchakool N 

PROVIDER: S-EPMC7493110 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature